Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs is well-positioned for future success with multiple potential catalysts on the horizon, including progress towards clinical execution of GEO-MVA and the initiation of a Phase 2 trial for Gedeptin in combination with an immune checkpoint inhibitor. Additionally, the distinctive attributes of its GEO-CM04S1 COVID-19 vaccine, such as targeting multiple antigens, make it a desirable candidate for commercialization in immunocompromised and high-risk populations. Despite reporting a decline in revenue and net loss for 2025, the company's strong focus on R&D and cost management highlights its commitment to advancing its innovative pipeline and achieving its ultimate goal of bringing novel treatments to market.

Bears say

Geovax Labs is facing a constrained near-term outlook due to limited near-term catalysts and tightening capital resources, prompting a downgrade from Buy to Hold. While the company has a strong focus on developing MVA-based vaccines for infectious diseases and solid tumor cancers, the potential value realization for these programs is delayed, with targeted data not expected until 2027. Furthermore, with a low cash balance and recent $1M financing, the company may face heightened dilution risk in the future, making it a risky investment in the short term.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of May 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.